Agenus (AGEN) Receives Price Target

Agenus (AGEN) : 3 investment research analysts covering Agenus (AGEN) have an average price target of $8 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $7 for the short term. Analysts expect the variance to be within $1.73 of the average price.

Agenus (AGEN) : 4 brokerage houses believe that Agenus (AGEN) is a Strong Buy at current levels. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.


Also, Major Brokerage house, Jefferies maintains its ratings on Agenus (NASDAQ:AGEN). In the latest research report, Jefferies raises the target price from $6 per share to $7 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on July 29, 2016.

Agenus (NASDAQ:AGEN): The stock was completely flat for the day, closing at $6.19 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $6.20, the stock touched an intraday high of $6.27 and a low of $6.04. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $6.19. The total trading volume on Thursday was 925,191.

Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *